The Recall Desk
LowFDA (Drugs)·D-1537-2014·Announced 2014-08-20

Pfizer Recalls Depo-Medrol Vials Due to pH Specification Failure

Pfizer is recalling 93,800 vials of Depo-Medrol (methylprednisolone acetate) because a stability test showed a pH level below the registered specification.

What this means for you

Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.

Our severity reasoning: The FDA classified this as a Class III recall, which by definition is unlikely to cause adverse health consequences, fitting the 'Low' severity criteria for documentation or specification issues without reported harm.

Plain-English summary

Pfizer Inc. is recalling 93,800 vials of Depo-Medrol (methylprednisolone acetate) injectable suspension, 40 mg/mL, 1 mL single-dose vials. The affected products are distributed nationwide and include Lot H43272 and H43265, which have an expiration date of 09/14.

The recall was initiated because a pH result of 2.9 was obtained at the 9-month stability test interval at 25C/60%RH. This result falls below the registered specification for pH, which is 3.0 - 7.0.

The FDA has classified this recall as Class III, indicating that use of or exposure to the violative product is not likely to cause adverse health consequences. Healthcare providers and patients should discontinue use of the affected lots and contact Pfizer for further instructions.

The recalled product

Product
DEPO-MEDROL (METHYLPREDNISOLONE ACETATE)
Brand
DEPO-MEDROL
Manufacturer
Pfizer Inc.
Affected units
93,800

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot H43272
  • H43265 Exp. 09/14

Distribution

Distributed nationwide across the United States.